


## Peer-Reviewed: Randomized Controlled Trial in Nigeria Shows Ivermectin Exhibits Positive Clinical Benefit in Mild to Moderate COVID-19



By [TrialSite Staff](#) February 19, 2021

[TrialsiteN](#) 

[africa](#) [covid-19](#) [ivercovid](#) [ivermectin](#) [nigeria](#) [positive results](#)



Like 4



***TrialSite recently introduced the Nigerian-based IVERCOVID study. In an interview with the principal investigator Professor Olufemi Babalola, an ophthalmologist and owner of Rachel Eye Center, he shared that the translational proof of concept (PoC) randomized, double blind placebo dose response study involving three treatment groups and 62 patients produced promising results. Dr. Babalola informed TrialSite that the study would be published soon and sure enough, this just occurred and hence this entry. The British peer-reviewed QJM, An International Journal of Medicine publishes this important small Lagos-based PoC study. Sparked by Vice President [Yemi Osinbajo's](#) interest in stimulating a biomedical research culture in what is both the most populated nation and the largest economy on the African continent, Dr. Babalola with colleagues including Professors Chris Bode and Adesuyi Ajayi and peers concluded that sufficient evidence not only supports investment in broader ivermectin-based research programs but also that a drug well-known to Nigeria should be considered for use in clinical management of COVID-19. The use of this economical and available generic drug should be at least investigated further, with a consideration for community prophylaxis initiatives targeting high-risk areas.***

As *TrialSite* reported in an interview with Professor Olufemi Babalola, that the nation's vice president expressed real interest in their IVERCOVID work compelled him and colleagues to organize the PoC study. One that included three (3) groups, including 1) ivermectin 6mg regime, 2) 12 mg regimen of ivermectin given Q84 hours for 2 weeks, and 3) control group given Lopinavir/Ritonavir. All groups also received the standard of care.

### Explore Further



Belgian Virologist Proposes a Plan to Eradicate COVID-19 in 6 Weeks Using Ivermectin

Well-Respected Australian Researcher:  
Consider Triple Therapy (Ivermectin, Zinc

The team established the Days to COVID negativity (DTN) as the primary endpoint for the study. They report ivermectin markedly reduces duration of SARS-CoV-2 infection from 9 days in the placebo group to 4.3 days in the study drug group. They observed no serious adverse events. Other findings can be reviewed at the source in the *QJM, An International Journal of Medicine*.

**Evidence? A Mounting Tally of Ivermectin Study Data**



News



Video



Podcast



More



Health Organization via its animated partner Omnicore contribute a meta-analysis authored by the UK's [Dr. Andrew Hill](#), the UK's [Dr. Tess Lawrie](#) also maintains a compelling aggregate of data. In the United States, the doctors behind the COVID-19 Critical Care (FLCCC) Alliance not only produced a ivermectin and COVID-19 clinical trial meta-analysis, but also have been active in educating the public about the data. They are serving this important role as most established medical societies keep distance from the topic, at least presently.

*TrialSite* has pointed to the @CovidAnalysis' well-done meta-analysis, delineating the data associated with the growing tally of studies. Most recently, [@CovidAnalysis](#) shared their latest ivermectin meta-analysis involving 41 studies, all of which report positive data points for the use of the drug in relation to COVID-19. [See the link](#) for their results. A total of 14,833 patients are involved for the combined 41 randomized controlled trials and observational studies under their count. While isolating the 20 RTCs, the patient count now stands at 2,796.

[Nigeria's IVERCOVID team](#), combined with studies in Egypt, Iraq, Mexico, Brazil, Argentina, Spain, Bangladesh, India and elsewhere, including a prominent case series study in the U.S., point to an undeniable trend.

### Lead Research/Investigator

[Professor Olufemi Babalola](#)

[Professors Chris Bode](#)


[Professor Adesuyi Ajayi](#)

 Follow the TSN COVID-19 Channel

### Related



Nigeria Government Making Moves to Fund Ivermectin Research Targeting COVID-19: IVERCOVID Program




A Progressive Vice-President & A Doctor Led & Financed Ivermectin Study in Nigeria: The IVERCOVID Back Story



Ivermectin Shows Potential as a Promising COVID-19 Prophylactic According to Study Published in Peer-Review Journal

### Explore Further



Write for us - we are expanding our list of external authors



Zimbabwe Officials Green Light Massive Importation of Ivermectin to Treat COVID-19



COVID-19 Vaccine Lead Israel Still Doesn't Experience Marked Reduction in Daily Cases: Situation Should be Monitored

Powered by

Source: [Oxford Academic](#)



News



Video



Podcast



More



Sign in to join the discussion

[Sign In](#)

[Comments](#) [Privacy](#) [Policy](#)

159 W Broadway, Suite 200  
Salt Lake City, UT 84101

[admin@trialsitenews.com](mailto:admin@trialsitenews.com)

### Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.



[News](#)



[Video](#)



[Podcast](#)



[More](#)